Genomic Landscape of Human Papillomavirus–Associated Cancers

Por Rusan, Maria, Li, Yvonne Y., Hammerman, Peter S.
Publicado no Clin Cancer Res (2015)

The Pim kinases control rapamycin-resistant T cell survival and activation

Por Fox, Casey J., Hammerman, Peter S., Thompson, Craig B.
Publicado em 2005

Therapeutic insights from genomic studies of head and neck squamous cell carcinomas

Por Hammerman, Peter S., Hayes, D. Neil, Grandis, Jennifer R.
Publicado no Cancer Discov (2015)

Targeted therapy for squamous cell lung cancer

Por Liao, Rachel G., Watanabe, Hideo, Meyerson, Matthew, Hammerman, Peter S.
Publicado em 2012

Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival

Por Hammerman, Peter S., Fox, Casey J., Birnbaum, Morris J., Thompson, Craig B.
Publicado em 2005

Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics

Por Gandara, David R., Hammerman, Peter S., Sos, Martin L., Lara, Primo N., Hirsch, Fred R.
Publicado no Clin Cancer Res (2015)

Challenges in EGFRvIII Detection in Head and Neck Squamous Cell Carcinoma

Por Wheeler, Sarah E., Egloff, Ann Marie, Wang, Lin, James, C. David, Hammerman, Peter S., Grandis, Jennifer R.
Publicado no PLoS One (2015)

The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor

Por Fox, Casey J., Hammerman, Peter S., Cinalli, Ryan M., Master, Stephen R., Chodosh, Lewis A., Thompson, Craig B.
Publicado em 2003

Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival

Por Rathmell, Jeffrey C., Fox, Casey J., Plas, David R., Hammerman, Peter S., Cinalli, Ryan M., Thompson, Craig B.
Publicado em 2003

Genomic analysis of metastatic cutaneous squamous cell carcinoma

Por Li, Yvonne Y., Hanna, Glenn J., Laga, Alvaro C., Haddad, Robert I., Lorch, Jochen H., Hammerman, Peter S.
Publicado no Clin Cancer Res (2015)

Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer

Por Terai, Hideki, Tan, Li, Beauchamp, Ellen M., Hatcher, John M., Liu, Qingsong, Meyerson, Matthew, Gray, Nathanael S., Hammerman, Peter S.
Publicado no ACS Chem Biol (2015)

The impact of the MYB-NFIB fusion proto-oncogene in vivo

Por Mikse, Oliver R., Tchaicha, Jeremy H., Akbay, Esra A., Chen, Liang, Bronson, Roderick T., Hammerman, Peter S., Wong, Kwok-Kin
Publicado no Oncotarget (2016)

Multiple signaling pathways promote B lymphocyte stimulator–dependent B-cell growth and survival

Por Woodland, Robert T., Fox, Casey J., Schmidt, Madelyn R., Hammerman, Peter S., Opferman, Joseph T., Korsmeyer, Stanley J., Hilbert, David M., Thompson, Craig B.
Publicado em 2008

Ligand associated ERBB2/3 activation confers acquired resistance to FGFR inhibition in FGFR3 dependent cancer cells

Por Wang, Jun, Mikse, Oliver, Liao, Rachel G., Li, Yvonne, Tan, Li, Janne, Pasi A., Gray, Nathanael S., Wong, Kwok-kin, Hammerman, Peter S.
Publicado no Oncogene (2014)

Cytokine stimulation of aerobic glycolysis in hematopoietic cells exceeds proliferative demand

Por Bauer, Daniel E., Harris, Marian H., Plas, David R., Lum, Julian J., Hammerman, Peter S., Rathmell, Jeffrey C., Riley, James L., Thompson, Craig B.
Publicado no FASEB J (2004)

Treatment-related Toxicities in a Phase II Trial of Dasatinib in Patients with Squamous Cell Carcinoma of the Lung: A Brief Report

Por Brunner, Andrew M., Costa, Daniel B., Heist, Rebecca S., Garcia, Elizabeth, Lindeman, Neal I., Sholl, Lynette M., Oxnard, Geoffrey R., Johnson, Bruce E., Hammerman, Peter S.
Publicado em 2013

NSCLC Driven by DDR2 Mutation is Sensitive to Dasatinib and JQ1 Combination Therapy

Por Xu, Chunxiao, Buczkowski, Kevin A., Zhang, Yanxi, Asahina, Hajime, Beauchamp, Ellen M., Terai, Hideki, Li, Yvonne Y., Meyerson, Matthew, Wong, Kwok-kin, Hammerman, Peter S.
Publicado no Mol Cancer Ther (2015)

Acquired resistance to dasatinib in lung cancer cell lines conferred by DDR2 gatekeeper mutation and NF1 loss

Por Beauchamp, Ellen M., Woods, Brittany A., Dulak, Austin M., Tan, Li, Xu, Chunxiao, Gray, Nathanael S., Bass, Adam J., Wong, Kwok-kin, Meyerson, Matthew, Hammerman, Peter S.
Publicado em 2013

Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

Por Dutt, Amit, Ramos, Alex H., Hammerman, Peter S., Mermel, Craig, Cho, Jeonghee, Sharifnia, Tanaz, Chande, Ajit, Tanaka, Kumiko Elisa, Stransky, Nicolas, Greulich, Heidi, Gray, Nathanael S., Meyerson, Matthew
Publicado em 2011

Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application

Por Chae, Young Kwang, Ranganath, Keerthi, Hammerman, Peter S., Vaklavas, Christos, Mohindra, Nisha, Kalyan, Aparna, Matsangou, Maria, Costa, Ricardo, Carneiro, Benedito, Villaflor, Victoria M., Cristofanilli, Massimo, Giles, Francis J.
Publicado no Oncotarget (2016)